Sildenafil Actavis

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

sildenafil

Available from:

Actavis Group PTC ehf

ATC code:

G04BE03

INN (International Name):

sildenafil

Therapeutic group:

Urologicals

Therapeutic area:

Poremećaj erekcije

Therapeutic indications:

Liječenje muškaraca s erektilnom disfunkcijom, što je nemogućnost postizanja ili održavanja erekcije penisa dovoljnih za zadovoljavajuće seksualne rezultate. Kako bi Sildenafil Актавис biti učinkovit, potrebno seksualnu stimulaciju .

Product summary:

Revision: 17

Authorization status:

odobren

Authorization date:

2009-12-10

Patient Information leaflet

                                30
B. UPUTA O LIJEKU
31
UPUTA O LIJEKU: INFORMACIJA ZA BOLESNIKA
SILDENAFIL ACTVIS 25 MG, 50 MG I 100 MG FILMOM OBLOŽENE TABLETE
SILDENAFIL ACTAVIS 25 MG FILMOM OBLOŽENE TABLETE
SILDENAFIL ACTAVIS 50 MG FILMOM OBLOŽENE TABLETE
SILDENAFIL ACTAVIS 100 MG FILMOM OBLOŽENE TABLETE
sildenafil
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE UZIMATI OVAJ
LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se svom liječniku, ljekarniku
ili medicinskoj sestri.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika, ljekarnika ili medicinsku
sestru. To uključuje i svaku moguću nuspojavu koja nije navedena u
ovoj uputi. Pogledajte dio
4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Sildenafil Actavis i za što se koristi
2.
Što morate znati prije nego počnete uzimati Sildenafil Actavis
3.
Kako uzimati Sildenafil Actavis
4.
Moguće nuspojave
5.
Kako čuvati Sildenafil Actavis
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE SILDENAFIL ACTAVIS I ZA ŠTO SE KORISTI
Sildenafil Actavis sadrži djelatnu tvar sildenafil koja pripada
skupini lijekova pod nazivom inhibitori
fosfodiesteraze tipa 5 (PDE5). Svojim djelovanjem omogućuje
opuštanje krvnih žila penisa čime
omogućuje dotok krvi u penis prilikom seksualnog uzbuđenja.
Sildenafil Actavis će Vam pomoći u
postizanju erekcije jedino ako ste seksualno stimulirani.
Sildenafil Actavis je lijek namijenjen liječenju odraslih muškaraca
s erektilnom disfunkcijom, ponekad
zvanom impotencija. Do toga dolazi kada muškarac nije u mogućnosti
postići ili održati ukrućenost
penisa u mjeri dovoljnoj za primjerenu spolnu aktivnost.
2.
ŠTO MORATE ZNATI PRIJE NEGO POČNETE UZIMATI SILDENAFIL ACTAVIS
NEMOJTE UZIMATI SILDENAFIL ACTAVIS
-
Ako ste alergični na sildenafil ili neki drugi sastojak ovog lijeka
(naveden u dijel
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Sildenafil Actavis 25 mg filmom obložene tablete
Sildenafil Actavis 50 mg filmom obložene tablete
Sildenafil Actavis 100 mg filmom obložene tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedna tableta sadrži 25, 50 ili 100 mg sildenafila u obliku
sildenafilcitrata.
Pomoćna tvar s poznatim učinkom
Sildenafil Actavis 25 mg tablete
Jedna tableta sadrži 62,38 mg laktoze (u obliku hidrata).
Sildenafil Actavis 50 mg tablete
Jedna tableta sadrži 124,76 mg laktoze (u obliku hidrata).
Sildenafil Actavis 100 mg tablete
Jedna tableta sadrži 249,52 mg laktoze (u obliku hidrata).
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložena tableta.
Sildenafil Actavis 25 mg filmom obložene tablete
Sildenafil Actavis 25 mg filmom obložene tablete su plave,
eliptičnog oblika, bikonveksne, dimenzija
10,0 x 5,0 mm, s oznakom „SL25“ na jednoj strani.
Sildenafil Actavis 50 mg filmom obložene tablete
Sildenafil Actavis 50 mg filmom obložene tablete su plave,
eliptičnog oblika, bikonveksne, dimenzija
13,0 x 6,5 mm, s oznakom „SL50“ na jednoj strani.
Sildenafil Actavis 100 mg filmom obložene tablete
Sildenafil Actavis 100 mg filmom obložene tablete su plave,
eliptičnog oblika, bikonveksne,
dimenzija 17,0 x 8,5 mm, s oznakom „SL100“ na jednoj strani.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Sildenafil Actavis je indiciran u odraslih muškaraca s erektilnom
disfunkcijom, odnosno
nemogućnošću postizanja ili održavanja penilne erekcije dostatne
za zadovoljavajuću seksualnu
aktivnost.
Kako bi Sildenafil Actavis djelovao, neophodna je seksualna
stimulacija.
3
4.2
DOZIRANJE I NAČIN PRIMJENE
Doziranje
_Primjena u odraslih osoba _
Preporučena doza iznosi 50 mg i uzima se po potrebi približno jedan
sat prije spolne aktivnosti. S
obzirom na djelotvornost i podnošljivost, doza se može povisiti do
100 mg ili sniziti do 25 mg.
Najviša preporučena doza je 100 mg. Najveća preporučena
učestalost doziranja iznosi 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 13-11-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 13-11-2023
Public Assessment Report Public Assessment Report Bulgarian 11-05-2015
Patient Information leaflet Patient Information leaflet Spanish 13-11-2023
Public Assessment Report Public Assessment Report Spanish 11-05-2015
Patient Information leaflet Patient Information leaflet Czech 13-11-2023
Public Assessment Report Public Assessment Report Czech 11-05-2015
Patient Information leaflet Patient Information leaflet Danish 13-11-2023
Public Assessment Report Public Assessment Report Danish 11-05-2015
Patient Information leaflet Patient Information leaflet German 13-11-2023
Public Assessment Report Public Assessment Report German 11-05-2015
Patient Information leaflet Patient Information leaflet Estonian 13-11-2023
Public Assessment Report Public Assessment Report Estonian 11-05-2015
Patient Information leaflet Patient Information leaflet Greek 13-11-2023
Public Assessment Report Public Assessment Report Greek 11-05-2015
Patient Information leaflet Patient Information leaflet English 13-11-2023
Public Assessment Report Public Assessment Report English 11-05-2015
Patient Information leaflet Patient Information leaflet French 13-11-2023
Public Assessment Report Public Assessment Report French 11-05-2015
Patient Information leaflet Patient Information leaflet Italian 13-11-2023
Public Assessment Report Public Assessment Report Italian 11-05-2015
Patient Information leaflet Patient Information leaflet Latvian 13-11-2023
Public Assessment Report Public Assessment Report Latvian 11-05-2015
Patient Information leaflet Patient Information leaflet Lithuanian 13-11-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 13-11-2023
Public Assessment Report Public Assessment Report Lithuanian 11-05-2015
Patient Information leaflet Patient Information leaflet Hungarian 13-11-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 13-11-2023
Public Assessment Report Public Assessment Report Hungarian 11-05-2015
Patient Information leaflet Patient Information leaflet Maltese 13-11-2023
Public Assessment Report Public Assessment Report Maltese 11-05-2015
Patient Information leaflet Patient Information leaflet Dutch 13-11-2023
Public Assessment Report Public Assessment Report Dutch 11-05-2015
Patient Information leaflet Patient Information leaflet Polish 13-11-2023
Public Assessment Report Public Assessment Report Polish 11-05-2015
Patient Information leaflet Patient Information leaflet Portuguese 13-11-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 13-11-2023
Public Assessment Report Public Assessment Report Portuguese 11-05-2015
Patient Information leaflet Patient Information leaflet Romanian 13-11-2023
Public Assessment Report Public Assessment Report Romanian 11-05-2015
Patient Information leaflet Patient Information leaflet Slovak 13-11-2023
Public Assessment Report Public Assessment Report Slovak 11-05-2015
Patient Information leaflet Patient Information leaflet Slovenian 13-11-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 13-11-2023
Public Assessment Report Public Assessment Report Slovenian 11-05-2015
Patient Information leaflet Patient Information leaflet Finnish 13-11-2023
Public Assessment Report Public Assessment Report Finnish 11-05-2015
Patient Information leaflet Patient Information leaflet Swedish 13-11-2023
Public Assessment Report Public Assessment Report Swedish 11-05-2015
Patient Information leaflet Patient Information leaflet Norwegian 13-11-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 13-11-2023
Patient Information leaflet Patient Information leaflet Icelandic 13-11-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 13-11-2023

Search alerts related to this product